Bio-Techne Declares Dividend
Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2024. The dividend will be paid on February 28, 2025, to shareholders of record as of February 17, 2025.
The company, a global life sciences organization providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024. Bio-Techne employs around 3,100 people worldwide and maintains a portfolio of thousands of products supporting scientific investigations, biological processes research, drug discovery, and clinical testing.
Bio-Techne (NASDAQ: TECH) ha annunciato un dividendo trimestrale di 0,08 $ per azione per il trimestre conclusosi il 31 dicembre 2024. Il dividendo sarà pagato il 28 febbraio 2025 agli azionisti registrati al 17 febbraio 2025.
L'azienda, un'organizzazione globale nel settore delle scienze della vita che fornisce strumenti innovativi e reagenti bioattivi per la ricerca e la diagnostica clinica, ha riportato vendite nette di circa 1,2 miliardi di dollari nell'anno fiscale 2024. Bio-Techne impiega circa 3.100 persone in tutto il mondo e mantiene un portafoglio di migliaia di prodotti a supporto delle indagini scientifiche, della ricerca sui processi biologici, della scoperta di farmaci e dei test clinici.
Bio-Techne (NASDAQ: TECH) ha anunciado un dividendo trimestral de 0,08 $ por acción para el trimestre que finalizó el 31 de diciembre de 2024. El dividendo se pagará el 28 de febrero de 2025 a los accionistas registrados hasta el 17 de febrero de 2025.
La empresa, una organización global de ciencias de la vida que proporciona herramientas innovadoras y reactivos bioactivos para la investigación y el diagnóstico clínico, reportó ventas netas de aproximadamente 1.2 mil millones de dólares en el año fiscal 2024. Bio-Techne emplea a alrededor de 3,100 personas en todo el mundo y mantiene un portafolio de miles de productos que apoyan investigaciones científicas, investigación de procesos biológicos, descubrimiento de fármacos y pruebas clínicas.
Bio-Techne (NASDAQ: TECH)는 2024년 12월 31일로 마감되는 분기에 대한 주당 0.08달러의 분기 배당금을 발표했습니다. 배당금은 2025년 2월 28일에 2025년 2월 17일 기준 주주에게 지급됩니다.
이 회사는 연구 및 임상 진단을 위한 혁신적인 도구 및 생리활성 시약을 제공하는 글로벌 생명 과학 조직으로, 2024 회계연도에 약 12억 달러의 순매출을 신고했습니다. Bio-Techne는 전 세계적으로 약 3,100명의 직원을 고용하고 있으며, 과학 조사, 생물학적 과정 연구, 신약 개발 및 임상 시험을 지원하는 수천 개의 제품 포트폴리오를 보유하고 있습니다.
Bio-Techne (NASDAQ: TECH) a annoncé un dividende trimestriel de 0,08 $ par action pour le trimestre se terminant le 31 décembre 2024. Le dividende sera payé le 28 février 2025 aux actionnaires enregistrés au 17 février 2025.
L'entreprise, une organisation mondiale des sciences de la vie fournissant des outils innovants et des réactifs bioactifs pour la recherche et le diagnostic clinique, a déclaré des ventes nettes d'environ 1,2 milliard de dollars pour l'exercice 2024. Bio-Techne emploie environ 3 100 personnes dans le monde et maintient un portefeuille de milliers de produits soutenant les enquêtes scientifiques, la recherche sur les processus biologiques, la découverte de médicaments et les tests cliniques.
Bio-Techne (NASDAQ: TECH) hat eine vierteljährliche Dividende von 0,08 $ pro Aktie für das am 31. Dezember 2024 endende Quartal angekündigt. Die Dividende wird am 28. Februar 2025 an die zum 17. Februar 2025 eingetragenen Aktionäre ausgezahlt.
Das Unternehmen, eine globale Organisation im Bereich der Lebenswissenschaften, die innovative Werkzeuge und bioaktive Reagenzien für Forschung und klinische Diagnostik bereitstellt, meldete im Geschäftsjahr 2024 einen Nettoumsatz von etwa 1,2 Milliarden Dollar. Bio-Techne beschäftigt weltweit etwa 3.100 Mitarbeiter und verfügt über ein Portfolio von Tausenden von Produkten, die wissenschaftliche Untersuchungen, Forschung zu biologischen Prozessen, Arzneimittelentdeckung und klinische Tests unterstützen.
- Generated $1.2 billion in net sales for fiscal 2024
- Maintains consistent quarterly dividend payment
- Extensive product portfolio serving research and clinical diagnostic markets
- None.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302368598.html
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's (TECH) quarterly dividend amount for Q4 2024?
When will Bio-Techne (TECH) pay its latest declared dividend?
What were Bio-Techne's (TECH) net sales in fiscal 2024?
How many employees does Bio-Techne (TECH) have globally?
What is the record date for Bio-Techne's (TECH) latest dividend?
